AstraZeneca PLC Website

AstraZeneca PLC

LSE-AZN

Basic

  • Market Cap

    £186.96B

  • EV

    £208.05B

  • Shares Out

    1,550.27M

  • Revenue

    $49.13B

  • Employees

    89,900

Margins

  • Gross

    82.62%

  • EBITDA

    34.55%

  • Operating

    25.13%

  • Pre-Tax

    15.77%

  • Net

    13.11%

  • FCF

    19.18%

Returns (5Yr Avg)

  • ROA

    3.67%

  • ROTA

    -204.57%

  • ROE

    12.68%

  • ROCE

    10.32%

  • ROIC

    8.24%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    £139.19

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $7,076M

  • Net Debt

    $26.57B

  • Debt/Equity

    0.85

  • EBIT/Interest

    9.65

Growth (CAGR)

  • Rev 3Yr

    18.5%

  • Rev 5Yr

    16.32%

  • Rev 10Yr

    6.44%

  • Dil EPS 3Yr

    12.79%

  • Dil EPS 5Yr

    19.2%

  • Dil EPS 10Yr

    9.9%

  • Rev Fwd 2Yr

    10.07%

  • EBITDA Fwd 2Yr

    25.87%

  • EPS Fwd 2Yr

    13.23%

  • EPS LT Growth Est

    13.45%

Dividends

  • Yield

    —

  • Payout

    71.44%

  • DPS

    $2.97

  • DPS Growth 3Yr

    1.98%

  • DPS Growth 5Yr

    1.19%

  • DPS Growth 10Yr

    0.59%

  • DPS Growth Fwd 2Yr

    5.85%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Operating Revenues

24,384

26,617

37,417

44,351

45,811

49,133

Other Revenues, Total

—

—

—

—

—

—

—

—

Total Revenues

24,384

26,617

37,417

44,351

45,811

49,133

Total Revenues % Chg.

10.4%

9.2%

40.6%

18.5%

3.3%

10.4%

Cost of Goods Sold, Total

4,848

5,246

12,005

8,619

8,040

8,540

Gross Profit

19,536

21,371

25,412

35,732

37,771

40,593

Selling General & Admin Expenses, Total

11,438

11,586

14,673

17,422

18,025

18,268

R&D Expenses

5,349

5,901

8,049

9,529

10,299

10,955

Other Operating Expenses

-319

-486

-207

-231

-987

-977

Other Operating Expenses, Total

16,468

17,001

22,515

26,720

27,337

28,246

Operating Income

3,068

4,370

2,897

9,012

10,434

12,347

Interest Expense, Total

-780

-738

-776

-917

-1,219

-1,280

Interest And Investment Income

145

77

43

81

301

371

Net Interest Expenses

-635

-661

-733

-836

-918

-909

Income (Loss) On Equity Invest.

-116

-27

-64

-5

-12

-30

Currency Exchange Gains (Loss)

-30

-34

-20

-16

-34

-34

Other Non Operating Income (Expenses)

-542

-487

-478

-370

-292

-292

EBT, Excl. Unusual Items

1,745

3,161

1,602

7,785

9,178

11,082

Restructuring Charges

-347

-251

-1,283

-717

-467

-816

Merger & Related Restructuring Charges

—

—

—

—

—

—

—

—

-3,571

-137

-137

Gain (Loss) On Sale Of Investments

—

—

—

776

—

—

—

Gain (Loss) On Sale Of Assets

1,222

1,055

509

216

292

51

Asset Writedown

-1,036

-252

-2,069

-241

-434

-114

Legal Settlements

—

-610

9

-48

-789

-1,013

-1,013

Other Unusual Items

574

194

248

-182

-520

-1,307

EBT, Incl. Unusual Items

1,548

3,916

-265

2,501

6,899

7,746

Income Tax Expense

321

772

-380

-792

938

1,301

Earnings From Continuing Operations

1,227

3,144

115

3,293

5,961

6,445

Minority Interest

108

52

-3

-5

-6

-5

Net Income

1,335

3,196

112

3,288

5,955

6,440

Net Income to Common Incl Extra Items

1,335

3,196

112

3,288

5,955

6,440

Net Income to Common Excl. Extra Items

1,335

3,196

112

3,288

5,955

6,440

Total Shares Outstanding

1,312.1

1,312.7

1,549.4

1,549.8

1,550.2

1,550

Weighted Avg. Shares Outstanding

1,301

1,312

1,418

1,548

1,549

1,549

Weighted Avg. Shares Outstanding Dil

1,301

1,313

1,427

1,560

1,562

1,562

EPS

1

2.4

0.1

2.1

3.8

4.2

EPS Diluted

1

2.4

0.1

2.1

3.8

4.1

EBITDA

5,575

6,990

6,701

13,944

15,010

16,973

Effective Tax Rate

20.7%

19.7%

143.4%

-31.7%

13.6%

16.8%